Category

Cohort News

Addressing the Cost vs. Quality Conundrum: 3EO Health Receives FDA Emergency Use Authorization, Launches Groundbreaking Point of Care Technology

//
Categories
3EO’s novel technology enables up to 70% savings versus existing point of care molecular tests. Demonstrated strong clinical performance of 95% PPA and 100% NPA. Delivers enhanced ease-of-use via a preparation-free workflow. BOSTON–(BUSINESS WIRE)–3EO Health, a “Point of Life” diagnostics...
Read More →